Open access
Open access
Powered by Google Translator Translator

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

29 Aug, 2022 | 12:36h | UTC

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology

Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.